RxDoctor Payments Data

Muneer Al Zoby, MD

Pulmonary Disease · Batavia, OHNPI 1083942999

Payments from drug & device makers

$10,028in general payments, 2019–2025

Across 190 payments — averaging $52.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • GSK$1K
  • Johnson & Johnson$479
  • AstraZeneca$375
  • Regeneron Healthcare Solutions, Inc.$332
  • Sanofi$318
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,64016%
  • Food & beverage$3,68937%
  • Education$4,69947%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,028 in reported general payments places this provider in the 75th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$181,831
Medicare patients
502
Services billed
1,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,262$988,474
Dupixent PenDupilumab108$427,409
Breztri AerosphereBudesonide/Glycopyr/Formoterol345$239,415
Spiriva RespimatTiotropium Bromide149$95,663
Dupixent SyringeDupilumab21$77,949
Breo ElliptaFluticasone/Vilanterol116$60,450
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr93$47,422
Stiolto RespimatTiotropium Br/Olodaterol Hcl67$37,523
SymbicortBudesonide/Formoterol Fumarate133$35,153
Spiriva HandihalerTiotropium Bromide33$32,659
Roflumilast365$25,507
Albuterol Sulfate HfaAlbuterol Sulfate898$23,646
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate113$23,272
Tiotropium Bromide31$19,448
Incruse ElliptaUmeclidinium Bromide34$14,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,115$1,122,9491,541 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp, Pulmicort Flexhaler$375$290,816520 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$148$144,549236 claims
MerckDulera$159$10,43226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Batavia

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →